Details of the Drug Combination

General Information of Drug Combination (ID: DCH94U6)

• Drug Combination Name: Aminolevulinic Acid Hydrochloride + Topetecan
• Indication: Adenocarcinoma; Status: Investigative [1]
• Component Drugs:
  Aminolevulinic Acid Hydrochloride (DMWNHPC): Small molecular drug
  Topetecan (DMAE6LK): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: HCC-2998
  Zero Interaction Potency (ZIP) Score: 6.5
  Bliss Independence Score: 4.61
  Loewe Additivity Score: 4.57
  LHighest Single Agent (HSA) Score: 9.1

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Aminolevulinic Acid Hydrochloride

Disease Entry	ICD 11	Status	REF
Actinic keratosis	EK90.0	Approved	[2]

Aminolevulinic Acid Hydrochloride Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Protoporphyrinogen oxidase (PPOX)	TTNFMS9	PPOX_HUMAN	Modulator	[4]

Indication(s) of Topetecan

Disease Entry	ICD 11	Status	REF
Small-cell lung cancer	2C25.Y	Approved	[3]

Topetecan Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Inhibitor	[5]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adult T acute lymphoblastic leukemia	DCUBEF9	MOLT-4	Investigative	[6]

References

• [1] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020671.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [6] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966